ImmunoGen, a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that it has licensed the exclusive right to ...
<0> For Investors:ImmunoGen, Inc.Carol Hausner, 781-895-0600Executive Director, Investor Relations and Corporate CommunicationsorFor Media:The Yates NetworkBarbara Yates, 781-258-6153 </0> (NASDAQ: ...
ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target <0> For Investors:ImmunoGen, Inc.Carol Hausner, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results